GTC Biotherapeutics, Ovation to collaborate over anti-coagulant

06/24/2008 | Forbes · Reuters

GTC Biotherapeutics has entered into a deal worth up to $257 million with Ovation Pharmaceuticals to develop and market ATryn, an experimental treatment for hereditary anti-thrombin deficiency, in the U.S. GTC could receive up to $9 million in milestone payments upon approval of the drug, which has obtained orphan designation and fast-track status from the FDA.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care